Revista Peruana de Reumatología : Volumen 1 Nº 1, Año 1995 LIMA-PERU



1. Serratrice G. Role du Toxoplasme et des viruses dans les dermatopolymyositis. Press Med. 1988; 17 (19): 953-6.

2. Bradley W. Tandan R. Inflamatory Diseases o muscle. Kelly WN et al. Textbook of Rheurnatology, 3rd ed., Philadelphia: W. B. Saunders Company, 1988; 1277.

3. Matsubara S. et al. Acute Toxoplasma myositis: an immunphistochemical and ultrastructural study.acta Neuropathol Berl. 1990; 81(2): 223-7.

4. Wiley C, Neremberg M., Cros D and Soto-Aguilar M. HTLV-1 polymyositis in a patient also infected with the human immunodeficiency virus. N Eng J Med. 1989; 320: 992-5.

5. Brown M., Goldestein J. Agentes usados en el tratarniento de las hiperlipidemias. Goodman Aet al., ed. Las Bases farmacol6gicas de la terap6utica. Ed M6dica Panamericana. 1991; 865.

6. Gherardi R et al. Skeletal muscle toxoplasmosis in patients with acquired immunodeficiency syndrome: a clinical and pathological study. Ann Neurol. 1992; 32 (4): 535-42.

7. McCabe R, Remington J. Toxoplasma gondii. Mandell G. et al., Principles and Practice of infectious Diseases, 3rded., New York: Churchill Livingstone 1990;2097.

8. Lawrence J. Kagen. inflammatory Disorders of Muscle. Rheum Dis Clin North Am 1994; 20 (4).

9. Kagen L. Polymyositis/Dermatomyositis. Mac Carty D, Koopman W. Arthritis and Allied Conditions. Textbook of Rheumatology, 12th ed., Philadelphia: Lea & Febirger, 1993;1239.

10. Herland CC et al. Dermatomyositis responding to treatment of associated toxoplasmosis. Br j Dermatol. 1991; 125(l):76-8.


Regresar al Artículo